Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Blood (2025) 146 (Supplement 1): 6080.

https://doi.org/10.1182/blood-2025-6080

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

Clinician-assessed eastern cooperative oncology group performance status vs. patient-reported health-related quality of life: Insights from malignant lymphoma

Wei Qin, Zhaoxin Qian, Wendong Chen, Fangping Chen, Yajing Xu

Blood (2025) 146 (Supplement 1): 4509.

https://doi.org/10.1182/blood-2025-4509

Published: 2025

Journal Articles

Avatrombopag improves platelet engraftment after haploidentical hematopoietic stem cell transplantation: A randomized, double-blind, multicenter, placebo-controlled trial

Blood (2025) 146 (Supplement 1): 377.

https://doi.org/10.1182/blood-2025-377

Published: 2025

Journal Articles

The impact of additional cytogenetic abnormalities and complex karyotype on outcomes of adult patients with Philadelphia-positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in first complete remission: A study from the ALWP/EBMT

Blood (2025) 146 (Supplement 1): 6067.

https://doi.org/10.1182/blood-2025-6067

Published: 2025

Journal Articles

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

Blood (2025) 146 (Supplement 1): 843.

https://doi.org/10.1182/blood-2025-843

Published: 2025

Journal Articles

BuCy combined with cladribine and medium-dose cytarabine as an intensified conditioning regimen for allogeneic hematopoietic stem cell transplantation in T-ALL/lbl patients

Tingting Cheng, Yan Chen, Fangping Chen, Yajing Xu

Blood (2025) 146 (Supplement 1): 2421.

https://doi.org/10.1182/blood-2025-2421

Published: 2025

Journal Articles

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Blood (2025) 145 (17): 1876–1889.

https://doi.org/10.1182/blood.2024025694

Published: 2025

Includes: Supplemental data

Journal Articles

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Blood (2024) 144 (Supplement 1): 3165.

https://doi.org/10.1182/blood-2024-202790

Published: 2024

Journal Articles

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Blood (2024) 144 (Supplement 1): 2558.

https://doi.org/10.1182/blood-2024-204447

Published: 2024

Journal Articles

Efficacy and Safety of Brl-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer in Transfusion-Dependent β-Thalassemia

Biao Zheng, Rongrong Liu, Xinhua Zhang, Bin Fu, Yajing Xu, Jun Shi, Xiaoqin Feng, Li Wang, Chris Wang, Rongmei Liang, Lingzhi Tan, Fei Wang, Dali Li, Yuxuan Wu, Mingyao Liu, Yongrong Lai

Blood (2023) 142 (Supplement 1): 4995.

https://doi.org/10.1182/blood-2023-186031

Published: 2023

Journal Articles

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

Blood (2023) 142 (Supplement 1): 2925.

https://doi.org/10.1182/blood-2023-188489

Published: 2023

Journal Articles

A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Junyuan Qi, Lin Song, Xudong Wei, Zhimin Zhai, Anyou Wang, Daozi Jiang, Yang Liang, Fei Li, Zhongxing Jiang, Xuejun Zhang, Qunyi Guo, Hongmei Jing, Yajing Xu, Xiangmin Tong, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 2908.

https://doi.org/10.1182/blood-2023-183088

Published: 2023

Journal Articles

The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

Xiaoyu Zhang, Shulian Chen, Weihua Zhai, Yi He, Sizhou Feng, Mingzhe Han, Ting Niu, Yajing Xu, Guangxun Gao, Shengjin Fan, Zepin Zhou, Fang Zhou, Rui Xi, Li Liu, Wei Yang, Xi Zhang, Qifa Liu, Erlie Jiang

Blood (2023) 142 (Supplement 1): 474.

https://doi.org/10.1182/blood-2023-184477

Published: 2023

Journal Articles

A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study

Blood (2023) 142 (Supplement 1): 4951.

https://doi.org/10.1182/blood-2023-184407

Published: 2023

Journal Articles

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 4045–4046.

https://doi.org/10.1182/blood-2022-155901

Published: 2022

Journal Articles

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

Blood (2022) 140 (Supplement 1): 4733–4734.

https://doi.org/10.1182/blood-2022-164640

Published: 2022

Journal Articles

The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients

Shulian Chen, Xiaoyu Zhang, Weihua Zhai, Yi He, Sizhou Feng, Mingzhe Han, Ting Niu, Yajing Xu, Guangxun Gao, Shengjin Fan, Zeping Zhou, Fang Zhou, Xi Rui, Li Liu, Wei Yang, Qifa Liu, Xi Zhang, Erlie Jiang

Blood (2022) 140 (Supplement 1): 10467–10468.

https://doi.org/10.1182/blood-2022-165140

Published: 2022

Journal Articles

Preemptive Therapy Based on the Load and Time of EBV-Emia for Preventing EBV Related PTLD after Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective Multicenter Study

Can Liu, Ren Lin, Yu Wang, Fen Huang, MD, Zhiping Fan, MD, Shen Zhang, Yajing Xu, MD PhD, Ting Yang, Li Xuan, MD, Na Xu, Jieyu Ye, MD PhD, Jing Sun, Xiaojun Huang, MD, Qifa Liu, MD

Blood (2019) 134 (Supplement_1): 5693.

https://doi.org/10.1182/blood-2019-132106

Published: 2019

Journal Articles

Corticosteroids Combined with Cyclosporine a Is Superior to Corticosteroids As First-Line Treatment for Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

Weiran Lv, Hong Qu, Meiqing Wu, Zhiping Fan, MD, Fen Huang, Na Xu, PhD, Li Xuan, Ren Lin, Ke Zhao, Jing Sun, Yongrong Lai, MD, Yajing Xu, MD PhD, Qifa Liu, MD

Blood (2018) 132 (Supplement 1): 5736.

https://doi.org/10.1182/blood-2018-99-114043

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Clinician-assessed eastern cooperative oncology group performance status vs. patient-reported health-related quality of life: Insights from malignant lymphoma

Avatrombopag improves platelet engraftment after haploidentical hematopoietic stem cell transplantation: A randomized, double-blind, multicenter, placebo-controlled trial

The impact of additional cytogenetic abnormalities and complex karyotype on outcomes of adult patients with Philadelphia-positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in first complete remission: A study from the ALWP/EBMT

Phase 3 ESLIM-01 study: Final analysis of efficacy and safety of long-term treatment with sovleplenib in adults with chronic primary immune thrombocytopenia

BuCy combined with cladribine and medium-dose cytarabine as an intensified conditioning regimen for allogeneic hematopoietic stem cell transplantation in T-ALL/lbl patients

Targeting Enterobacter cloacae attenuates osteolysis by reducing ammonium in multiple myeloma

Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications

Long-Term Sovleplenib Treatment of Adults with Primary Immune Thrombocytopenia in China

Efficacy and Safety of Brl-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer in Transfusion-Dependent β-Thalassemia

Safety and Efficacy of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Relapsed or Refractory (R/R) or Treatment-Naïve (TN) Patients (Pts) with Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), or Other Myeloid Neoplasms

A Phase I/II Trial of the FLT3 Kinase Inhibitor XY0206 in Patients with Relapsed/Refractory Acute Myeloid Leukemia

The Modified Melphalan-Cladribine-Busulfan-Cyclophosphamide (MCBC) Conditioning Regimen Improved Relapse-Free Survival after Allo-HSCT in Refractory/Relapsed AML

A Prediction Model for Early Recurrence after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with CMML: A Nationwide Representative Multicenter Study

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

The Efficacy and Safety of Modified Melphalan and Busulfan-Based Conditioning Regimen for Allogeneic-HSCT in Refractory/Relapsed or Persistent MRD Positive AML Patients

Preemptive Therapy Based on the Load and Time of EBV-Emia for Preventing EBV Related PTLD after Haploidentical Hematopoietic Stem Cell Transplantation: A Prospective Multicenter Study

Corticosteroids Combined with Cyclosporine a Is Superior to Corticosteroids As First-Line Treatment for Autoimmune Hemolytic Anemia after Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only